111 Capital Regeneron Pharmaceuticals, Inc. Transaction History
111 Capital
- $476 Billion
- Q4 2024
A detailed history of 111 Capital transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, 111 Capital holds 531 shares of REGN stock, worth $357,023. This represents 0.08% of its overall portfolio holdings.
Number of Shares
531Holding current value
$357,023% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,495Shares Held
85.9MCall Options Held
1.53MPut Options Held
1.44M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.24 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.68 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$4.75 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.83MShares$3.25 Billion0.14% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$3.18 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $72.1B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...